Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: The AMALTHEA (Aflibercept MAintenance after first-Line THErapy with FOLFIRI+Aflibercept in metastatic colorectal cancer patients) trial is an investigator-initiated, single arm, open-label, phase II study. Patients with histologically proven metastatic colorectal carcinoma will be treated with a combination of FOLFIRI and aflibercept for 6 months. Both Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type (wt) and mutant (mut) patients wil be enrolled. In the absence of Progressive Disease (PD) after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicity, investigator’s decision or patient’s refusal of further treatment or death, whichever comes first.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Μεταστατικός Κολοορθικός Καρκίνος
PROVIDER: 2165895 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA
